NOVATO, Calif., Jan. 10, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq:RPTP) announced today the appointment of Patrick Reichenberger to the newly created position of Vice President, Commercial Operations. Additionally, Raptor has engaged Cambrex Corporation (NYSE:CMB) for the manufacturing of the active pharmaceutical ingredient (“API”), cysteamine bitartrate, and Patheon, Inc. (TSX:PTI) to produce the commercial product, DR Cysteamine.
